

# Clinical trial of WHO multibacillary multidrug therapy versus rifampicin, moxifloxacin and clarithromycin on multibacillary leprosy patients from India

<b>Submission date</b> 27/06/2024	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 08/07/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Protocol
<b>Last Edited</b> 06/01/2026	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

This clinical trial focuses on evaluating the effectiveness and safety of a new treatment for leprosy. Leprosy is a chronic infectious disease caused by the bacterium *Mycobacterium leprae*. The study aims to determine if the new treatment can reduce the bacterial load, achieve a complete clinical cure, and improve pathological (disease) markers in patients with leprosy.

### Who can participate?

Patients aged 15-60 years with multibacillary leprosy who have not received treatment

### What does the study involve?

Participants will receive the new treatment and undergo various assessments, including tests measuring bacterial load, clinical examinations to assess lesion regression and overall improvement, and tests to evaluate changes in the Bacillary Index (BI). These assessments will occur at the start of the study and after 3 months, 6 months, and 1 year.

### What are the possible benefits and risks of participating?

#### Benefits:

1. Participants may experience improvement in their leprosy symptoms.
2. Contribution to scientific knowledge that may help future patients with leprosy.

#### Risks:

1. Possible side effects of the treatment, ranging from mild to severe.
2. Regular follow-up visits and tests may be time-consuming.

### Where is the study run from?

The Leprosy Mission Trust India

### When is the study starting and how long is it expected to run for?

March 2023 to March 2027

Who is funding the study?  
Indian Council of Medical Research

Who is the main contact?  
Dr Joydeepa Darlong, joydeepa.darlong@leprosymission.in

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Joydeepa Darlong

### ORCID ID

<https://orcid.org/0000-0002-3242-8875>

### Contact details

16, Pandit Pant Marg  
CNI Bhavan  
New Delhi  
India  
110001  
+91 (0)9434885198  
joydeepa.darlong@leprosymission.in

### Type(s)

Scientific

### Contact name

Dr Itu Singh

### ORCID ID

<https://orcid.org/0000-0003-0596-8566>

### Contact details

Stanley Browne Laboratory  
TLM Community Hospital Shahdara  
Delhi  
India  
110093  
+91 (0)9717730549  
itu.singh@leprosymission.in

### Type(s)

Public

### Contact name

Dr Reeta Devi

**ORCID ID**

<https://orcid.org/0000-0002-4107-4271>

**Contact details**

TLM Community Hospital Shahdara  
Nand Nagari  
Delhi  
India  
110093  
+91 (0)6006203600  
reeta.devi@leprosymission.in

**Type(s)**

Public

**Contact name**

Dr Samrun Nessa

**Contact details**

TLM Community Hospital Shahdara  
Delhi  
India  
110093  
+91 (0)9110322091  
samrun.nessa@leprosymission.in

**Type(s)**

Public

**Contact name**

Dr Neeta Maximus

**Contact details**

TLM Hospital Barabanki  
Barabanki  
India  
225001  
+91 (0)9936566849  
neeta.maximus@leprosymission.in

**Type(s)**

Public

**Contact name**

Dr Vandana Elkana

**Contact details**

TLM Chandkhuri  
Bilaspur  
India  
495222

+91 (0)9981774449  
vandana.elkana@leprosymission.in

**Type(s)**  
Scientific

**Contact name**  
Dr Utpal Sengupta

**ORCID ID**  
<https://orcid.org/0000-0002-1177-1076>

**Contact details**  
Stanley Browne Laboratory  
TLM Community Hospital Shahdara  
Delhi  
India  
110093  
+91 (0)9212761651  
utpal.sengupta@leprosymission.in

**Type(s)**  
Scientific

**Contact name**  
Mr Karthikeyan Govindasamy

**ORCID ID**  
<https://orcid.org/0000-0001-5500-1308>

**Contact details**  
16, Pandit Pant Marg  
CNI bhavan  
New Delhi  
India  
100001  
+91 (0)9935284315  
karthikeyan.g@leprosymission.in

**Type(s)**  
Scientific

**Contact name**  
Dr Anamika Halder

**Contact details**  
The Leprosy Mission Home and Hospital  
Purulia, West Bengal  
India

723101  
+91 (0)8271855993  
anamika.haldar@leprosymission.in

### **Type(s)**

Scientific

### **Contact name**

Dr Ann Miriam Jose

### **Contact details**

Molecular Biology Lab  
Schieffelin Institute of Health – Research & Leprosy Centre (SIH-R & LC)  
Vellore  
India  
632106  
-  
annmjose97@gmail.com

## **Additional identifiers**

### **Clinical Trials Information System (CTIS)**

Nil known

### **ClinicalTrials.gov (NCT)**

Nil known

### **Protocol serial number**

CTRI/2024/03/064435

## **Study information**

### **Scientific Title**

A comparative multicentric non-inferiority clinical trial of WHO multibacillary multidrug therapy with a new monthly chemotherapy regimen containing rifampicin, moxifloxacin and clarithromycin on multibacillary patients from India

### **Acronym**

RMC

### **Study objectives**

Monthly rifampicin, moxifloxacin and clarithromycin (RMC) are as efficacious and safe as WHO multibacillary multidrug therapy (MBMDT) in patients affected by multibacillary leprosy.

### **Ethics approval required**

Ethics approval required

### **Ethics approval(s)**

approved 20/11/2023, TLMTI ethics Committee (16, Pandit Pant Marg, CNI Bhawan, New Delhi, 110001, India; +91 (0)9811912926; monicathomaschandy@gmail.com), ref: TLMTI/EC/C- 68

## **Study design**

Open-label randomized clinical control trial

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Leprosy

## **Interventions**

It is an open-label randomized clinical control non-inferiority trial where in the intervention group a monthly supervised regimen of rifampicin, moxifloxacin and clarithromycin will be administered in doses of 600 mg, 400 mg, and 1000 mg respectively once a month and the control arm would be given routine WHO MB MDT (rifampicin 600 mg, clofazimine 300 mg once monthly and clofazimine 50 and dapsone 100 mg daily). The duration of the treatment in both arms will be 12 months. The random sequence will be generated centrally which will be sent to study centers in opaque envelopes. After consent is approved, the envelope will be opened, and the patient will be put on the respective arms. The study population will include newly diagnosed, previously untreated MB leprosy patients. Written informed consent will be sought from every subject included in the study.

Slit skin smears of all the study subjects will be collected at baseline, 6 and 12 months and transported in RNA later to the SBL. Real-time PCR will be done to quantitate copy numbers of the genes encoding 16S rRNA, hsp18 and exsA specific for *M. leprae*. Resistance studies will be carried out at 12 months in patients harbouring viable bacilli. Validation of *M. leprae* growth in mouse foot pad will be performed on participants showing viable load by molecular methods at the time of RFT in Schieffelin Institute of Health – Research and Leprosy Centre Karigiri (SIHR&LC), Vellore.

## **Intervention Type**

Drug

## **Phase**

Phase III

## **Drug/device/biological/vaccine name(s)**

Rifampicin, moxifloxacin, clarithromycin, clofazimine, dapsone

## **Primary outcome(s)**

1. Molecular:

1.1. Reduction of copy numbers by molecular viability assay (MVA) measured using quantitative PCR (qPCR) at baseline, 1, 3, 6 and 12 months

1.2. Complete killing of *M. leprae* assessed using mouse foot pad (MFP) assay at release from treatment (RFT) (12 months)

2. Clinical:

2.1. Complete clinical cure, defined as full regression of the lesions, assessed through clinical examination at baseline, 6 months, and 1 year

2.2. Clinical improvement of the lesions measured by a clinical criterion (e.g., lesion size reduction) at baseline, 6 months, and 1 year

3. Pathological:

3.1. Bacillary Index (BI) improvement measured using skin smears and histopathological examination at baseline, 3 months, 6 months, and 1 year

### **Key secondary outcome(s)**

1. Immunological outcomes:

1.1. Neuritis measured through patient self-reporting of pain during interviews and nerve function tests (e.g., sensory and motor function tests) every month during the treatment period and thereafter 6 monthly for 1 year

1.2. Type I reaction assessed through clinical examination and patient reporting with type 1 reaction from the development of the reaction to its subsidence

1.3. Type II reaction assessed through clinical examination and patient reporting with type 2 reaction from the development of the reaction to its subsidence

2. Safety outcomes:

2.1. Severe side effects, defined as side effects that force the patient to stop treatment, monitored and recorded throughout the treatment period (baseline to 1 year)

2.2. Mild to moderate side effects monitored and recorded throughout the treatment period (baseline to 1 year)

3. Qualitative outcomes:

3.1. Impact of leprosy treatment on life assessed using patient interviews and quality of life questionnaires at 1 year

3.2. Perspective towards leprosy treatment assessed using patient interviews and attitude questionnaires at 1 year

### **Completion date**

31/03/2027

## **Eligibility**

### **Key inclusion criteria**

1. Age 15 years and above

2. Multibacillary (MB) leprosy, defined as 5 or more skin lesions or extensive infiltration and/or diffuse skin involvement, classified as borderline tuberculoid, borderline lepromatous or polar lepromatous, as determined using the Ridley and Jopling classification system

3. Never treated before for leprosy

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

### **Lower age limit**

15 years

### **Upper age limit**

70 years

**Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

1. History of intolerance to one of the medications
2. Patients who are not able to come to the clinic every month during their treatment and during follow-up
3. Patients who do not give informed consent or are not capable of giving informed consent due to mental impairment
4. Immunocompromised patients diagnosed with HIV/AIDS and tuberculosis

**Date of first enrolment**

02/07/2024

**Date of final enrolment**

31/01/2026

**Locations**

**Countries of recruitment**

India

**Study participating centre**

**The Leprosy Mission Home and Hospital**

Belguma

Puruliya

India

723101

**Study participating centre**

**The Leprosy Mission Hospital**

Leprosy Clinic

Barabanki

India

225001

**Study participating centre**

**The Leprosy Mission Hospital**

Chandkhuri

Chandkhuri

India  
495222

**Study participating centre**  
TLM Community Hospital  
Nandnagari  
Delhi  
India  
110093

## Sponsor information

**Organisation**  
The Leprosy Mission Trust India

## Funder(s)

**Funder type**  
Government

**Funder Name**  
Indian Council of Medical Research

**Alternative Name(s)**  
Indian Council of Medical Research, Government of India, Indian Council of Medical Research (ICMR), New Delhi, ICMROrganisation, , Indian Council of Medical Research, New Delhi, . . . , ICMR, ICMRDELHI, ...

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
National government

**Location**  
India

## Results and Publications

**Individual participant data (IPD) sharing plan**

## IPD sharing plan summary

Data sharing statement to be made available at a later date

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Other files</a>	Standard operating procedure documents		12/08/2024	No	No
<a href="#">Other files</a>		25/08/2023	19/08/2024	No	No
<a href="#">Participant information sheet</a>			01/07/2024	No	Yes
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes